newsfilter
← Latest News
Business Wire·

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial;